NCT03500380 2024-02-20
A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases
RemeGen Co., Ltd.
Phase 2/3 Unknown
Clinical Trials
10 trialsNCT04591431 2023-10-03
ROME
Fondazione per la Medicina Personalizzata
Phase 2 Unknown
NCT01104571 2018-09-17
EPHOS-B
Institute of Cancer Research, United Kingdom
Phase 3 Unknown
NCT03273595 2017-09-06
Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive Breast Cancer
Xijing Hospital
Phase 2 Unknown
NCT03085368 2017-07-28
A Randomized Controlled Trial of HER-2 Positive Breast Cancer Patients Treated With Lapatinib vs Herceptin
Peking Union Medical College Hospital
Phase 2/3 Unknown
NCT01283789 2017-02-08
Lapatinib and RAD-001 for HER2 Positive Metastatic Breast Cancer
University of Kansas Medical Center
Phase 2 Unknown
NCT02394496 2016-06-15
OVER
Consorzio Oncotech
Phase 3 Unknown
NCT01730677 2014-03-12
LV
National Cancer Center, Korea
Phase 2 Unknown
NCT00688194 2013-08-26
Fulvestrant With or Without Lapatinib and/or Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer That Progressed After Previous Aromatase Inhibitor Therapy
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00842998 2009-06-26
HERLAP
Azienda Ospedaliera Ordine Mauriziano di Torino
Phase 2 Unknown